Dasatinib, a small molecule inhibitor of the Src family of kinases, PDGFRα/β, and c-KIT, is currently the only TKI that has demonstrated activity against both chondrosarcoma (CS) and chordoma in a phase II clinical trial. Here, SRC is linked to chondrosarcoma.